Completed PHASE2 INTERVENTIONAL 2-arm NCT00325234

Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer

A Randomized Phase II Study of Two Chemotherapy Regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxanes Pretreated Advanced Breast Cancer Patients

Sponsor: Eli Lilly and Company

Conditions Breast Cancer

Interventions Carboplatin Gemcitabine Pemetrexed Vinorelbine

Updated 7 times since 2017 Last updated: Apr 26, 2011 Started: Jun 30, 2006 Primary completion: Apr 30, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Barcelona, Spain , Bergamo, Italy , Besevler/Ankara, Turkey (Türkiye) , Bologna, Italy , Bornova, Turkey (Türkiye) , Durban, South Africa , Girona, Spain , Gütersloh, Germany , Hamburg, Germany and 12 more locations